SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-013406
Filing Date
2022-07-29
Accepted
2022-07-28 17:55:59
Documents
12
Period of Report
2022-07-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K ikt-20220725.htm   iXBRL 8-K 52068
  Complete submission text file 0000950170-22-013406.txt   173085

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20220725_pre.xml EX-101.PRE 10290
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20220725_lab.xml EX-101.LAB 14010
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20220725.xsd EX-101.SCH 2472
6 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20220725_htm.xml XML 4917
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 221116549
SIC: 2836 Biological Products, (No Diagnostic Substances)